Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy
Forum of Clinical Oncology · 14.07.2026
DOI: 10.2478/fco-2024-0029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Forum of Clinical Oncology, online erschienen am 14.07.2026. Verfasst von Yi-Lun Wang und 2 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cytopenia is a common adverse effect following anti-cancer therapy. Among the various cell line reductions, neutropenia is most strongly associated with an increased risk of infection. Severe infections may further suppress hematopoietic function and thereby prolong cytopenic periods. Here, we present a case of relapsed and refractory leukemia with profound cytopenia and infectious complications following intensified chemotherapy. This case highlights the concept of an early and pronounced myelosuppressive effect in patients with impaired bone marrow function secondary to anti-neoplastic therapy. Clinicians should be particularly vigilant in recognizing the vulnerability of such patients to enable earlier detection and intervention.
Zitieren
APA
Wang, Y., Lee, W., & Jaing, T. (2026). Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy. Forum of Clinical Oncology. https://doi.org/10.2478/fco-2024-0029
Vancouver
Wang Y, Lee W, Jaing T. Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy. Forum of Clinical Oncology. 2026. doi:10.2478/fco-2024-0029
BibTeX
@article{Wang2026,
author = {Wang, Yi-Lun and Lee, Wan-Ju and Jaing, Tang-Her},
title = {Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy},
journal = {Forum of Clinical Oncology},
year = {2026},
doi = {10.2478/fco-2024-0029}
}
EUVIMED